Postconsolidation maintenance and monitoring in patients with acute promyelocytic leukemia
Chezi Ganzel1, Dan Douer, Martin S Tallman
1From the Leukemia Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York.
Abstract:
Acute promyelocytic leukemia (APL) is a unique subtype of acute myeloid leukemia (AML). Its exclusivity is reflected by both the clinical course and the management of patients. This article discusses 2 aspects of the unique management of patients with APL: the role of maintenance therapy and polymerase chain reaction (PCR) monitoring. Despite common practice, the efficacy of maintenance therapy in APL is still debated, and the introduction of arsenic trioxide into frontline protocols makes this debate even more challenging. This article also attempts to clarify details regarding the type and duration of maintenance treatment. The presence of residual leukemic cells, seen using PCR analysis of the PML/RARα fusion gene product, in patients who have experienced a complete response has been shown to have a high correlation with subsequent relapse. This fact led to the broad use of PCR monitoring techniques in patients with APL. Practicing clinicians face several questions with regard to monitoring, such as what is the best technique for monitoring patients with APL, who can benefit the most from these tests, what are the best time points, and for how long is monitoring recommended. These questions are addressed in this article.
Insights
This study examines maintenance therapy and PCR monitoring for acute promyelocytic leukemia (APL), a unique AML subtype. It clarifies treatment details and monitoring strategies for better patient outcomes.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Acute promyelocytic leukemia (APL) is a distinct subtype of acute myeloid leukemia (AML).
- APL management is unique, influenced by clinical course and treatment protocols.
- Evolving treatment strategies, including arsenic trioxide, necessitate re-evaluation of APL management.
Purpose of the Study:
- To discuss the role and efficacy of maintenance therapy in APL.
- To clarify optimal type and duration of maintenance treatment for APL patients.
- To address key questions regarding polymerase chain reaction (PCR) monitoring in APL.
Main Methods:
- Review of current literature on APL maintenance therapy.
- Analysis of the utility and application of PCR monitoring for residual disease detection.
- Discussion of clinical questions surrounding PCR monitoring in APL management.
Main Results:
- The efficacy of maintenance therapy in APL remains debated, especially with new frontline treatments.
- PCR detection of PML/RARα fusion gene product correlates with relapse risk in APL patients.
- Optimal PCR monitoring strategies, including timing and duration, require careful consideration.
Conclusions:
- Maintenance therapy in APL requires further investigation to define its precise role.
- PCR monitoring is crucial for detecting minimal residual disease and predicting relapse in APL.
- Standardized guidelines for PCR monitoring in APL are needed to optimize patient care.
Related Concept Videos
01:22Myocarditis IV: Nursing Management
01:15Differentiation of Common Myeloid Progenitor Cells